Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region.
Autor: | De Giorgi, Ugo1 (AUTHOR) ugo.degiorgi@irst.emr.it, Hussain, Maha2 (AUTHOR), Shore, Neal3 (AUTHOR), Fizazi, Karim4 (AUTHOR), Tombal, Bertrand5 (AUTHOR), Penson, David6 (AUTHOR), Saad, Fred7 (AUTHOR), Efstathiou, Eleni8 (AUTHOR), Madziarska, Katarzyna9 (AUTHOR), Steinberg, Joyce10 (AUTHOR), Sugg, Jennifer10 (AUTHOR), Lin, Xun11 (AUTHOR), Shen, Qi12 (AUTHOR), Sternberg, Cora N.1,13 (AUTHOR) cns9006@med.cornell.edu |
---|---|
Zdroj: | European Journal of Cancer. Dec2021, Vol. 159, p237-246. 10p. |
Databáze: | Academic Search Ultimate |
Externí odkaz: |